Organogenesis begins clinical trial of living skin replacement to promote wound healing.
The clinical study will administer Vitrix to 20 patients with diabetic foot ulcers. If the ulcers to not health within 12 weeks, the patients will receive Organogenesis' lead product Apligraf to complete the healing process. The company says Apligraf differs from Vitrix in that it is an actual cellular skin substitute consisting of living human epidermal cells, called keratinocytes, along with the dermal cells and collagen present in Vitrix.
About 800,000 people worldwide suffer from diabetic foot ulcers, which are responsible for 50,000 amputations a year.
Contact: (617) 575-0775; Web site: www.organogenesis.com
|Printer friendly Cite/link Email Feedback|
|Comment:||Organogenesis begins clinical trial of living skin replacement to promote wound healing.|
|Article Type:||Brief Article|
|Date:||Aug 30, 2001|
|Previous Article:||Thoratec submits IDE to FDA to expand number of patients in trial of its LVAS system.|
|Next Article:||Isotechnika says its experimental immunosuppressent drug to be administered in kidney transplant patient.|
|Novartis given approval by FDA to market Apligraf for the treatment of venous leg ulcers|
|FDA approves Novartis' Apligraf for treatment of diabetic foot ulcers.|
|BIOMARIN GETS POSITIVE DATA FROM VIBRILASE PHASE 1B TRIAL.|